Efficacy and Safety of Tildrakizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis of the Scalp: Week 52 Results From a Phase 3b, Randomized, Double-Blind, Placebo-Controlled Trial

By sjmartinez • December 26, 2024

Sofen HL, Gebauer K, Spelman L, Yamauchi PS, Yao SL, Nishandar T, Kopeloff I, Crane M, Gogineni R, Kothekar M, Bagel J. Efficacy and Safety of Tildrakizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis of the Scalp: Week 52 Results From a Phase 3b, Randomized, Double-Blind, Placebo-Controlled Trial. J Am Acad Dermatol. 2024 Dec 23:S0190-9622(24)03393-0. doi: 10.1016/j.jaad.2024.12.018. Epub ahead of print. PMID: 39722400.

Tags: Dermatology, efficacy, itch, Olive View DoM, psoriasis, Publications, safety, scalp, tildrakizumab

Racial/Ethnic Disparities in Cutaneous T-cell Lymphoma: A Clinical Review

Kakani P, Davis J. Racial/Ethnic Disparities in Cutaneous T-cell Lymphoma: A Clinical Review. Skinmed. 2024 Dec 31;22(6):422-426. PMID: 39748573.

An evaluation framework for clinical use of large language models in patient interaction tasks

Johri S, Jeong J, Tran BA, Schlessinger DI, Wongvibulsin S, Barnes LA, Zhou HY, Cai ZR, Van Allen EM, Kim D, Daneshjou R, Rajpurkar P.[...]

Treatment of pembrolizumab-induced bullous pemphigoid with dupilumab: A case report and review of the literature

Barghi A, Noveir SD, Mainwaring W, Milani-Nejad N, Bernet L. Treatment of pembrolizumab-induced bullous pemphigoid with dupilumab: A case report and review of the literature.[...]